Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
X-ray photons are packets of electromagnetic energy in the X-ray wavelength range (approximately 0.01–10 nanometers). They are produced by energy transitions in atoms, most commonly through interactions with a target material in an X-ray tube, via mechanisms such as Bremsstrahlung or characteristic emission. Biologically, X-ray photons interact with tissue, inducing ionization and generating free radicals, which can damage biomolecules such as DNA, proteins, and enzymes, either directly or indirectly through radiolysis of water. This mechanism underlies both their imaging utility and their therapeutic applications in radiation oncology, but also accounts for their safety risks, including mutagenesis, tissue injury, and increased cancer risk. X-ray photons are not considered a conventional drug target in pharmacology or molecular biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-ray photon.